Company profile

VERICEL CORP

NASDAQ:VCELBiotechnology: Biological Products (No Diagnostic Substances)

Drug pipeline (4)

Asset	Stage	Revenue	Trials	Status
MACI	approved	$65.5MQ2 2026	0	—
CARTICEL SM SERVICE	approved	—	1	approved
NEXOBRID	approved	—	0	—
NEXOBRID	approved	—	0	—

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (12)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT03588975	phase3	recruiting	2018-10-24	2030-02-01	Vericel Corporation	A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee
NCT06915233	phase3	recruiting	2026-05-28	2030-07-01	Vericel Corporation	A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle
NCT01483898	phase3	completed	2012-02-01	2014-03-25	Vericel Corporation	An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI)
NCT01670981	phase2	completed	2013-02-20	2016-02-01	Vericel Corporation	An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)
NCT00424567	phase1_2	terminated	2003-10-01	—	Vericel Corporation	Feasibility Study of Aastrom Tissue Repair Cells to Treat Non-Union Fractures.

FDA applications (3)

Application

Approved

Type

Applicant

Products

BLA 761192

2022-12-28

BLA

VERICEL CORPORATION

BLA 125603

2016-12-13

BLA

VERICEL CORPORATION

BLA 103661

1997-08-22

BLA

VERICEL CORPORATION